Literature DB >> 27479143

Elevated Liver Enzymes and Mortality in Older Individuals: A Prospective Cohort Study.

Suzanne E Mahady1, Germaine Wong, Robin M Turner, Paul Mitchell, Petra Macaskill, Jonathan C Craig, Jacob George.   

Abstract

AIM OF THE STUDY: The aim of the study was to determine the excess risk of all-cause and cardiovascular mortality in older people with elevated liver enzymes [alanine transaminase (ALT) and gamma glutamyltransferase (GGT)].
METHODS: We utilized data from a large, prospective, population based study of 2061 people aged 50 to 99 years with linkage to a National Death Registry. Participants were categorized as having elevated liver enzymes using standard thresholds (for males, GGT>51 and ALT>40 IU/L, and GGT>33 and ALT>31 IU/L for females). Adjusted Cox proportional hazards models assessed the association of elevated liver enzymes and mortality with long duration follow-up.
RESULTS: Over a median follow-up of 10 years (20,145 person years), 701 people died, including 203 (34%) from cardiovascular disease. Cox regression models adjusted for sex, age, smoking, and alcohol intake indicated that people with elevated liver enzymes had an increased risk of all-cause mortality that was modified by age (test for interaction P=0.01). Age-stratified analyses demonstrated no increased risk at younger ages [age 59 y and below; hazard ratio (HR): 0.46; 95% confidence interval, 0.06-3.49], but increased risk with age; age 60 to 69, HR: 1.05 (0.53-2.07), age 70 to 79 years, HR: 1.54 (0.81 to 2.93), and age 80 years and above, HR: 3.53 (1.55 to 8.04). Similarly, the risk of cardiovascular mortality with elevated liver enzymes was also modified by, and increased with age (test for interaction P=0.02); age 70 to 79, HR: 3.15 (1.37 to 7.23), age 80 years and above, HR: 6.86 (2.44 to 19.30).
CONCLUSIONS: In community-dwelling elderly persons, an elevation in both ALT and GGT are associated with an excess risk of all-cause and cardiovascular mortality which increases with age.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27479143     DOI: 10.1097/MCG.0000000000000622

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  6 in total

Review 1.  Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology.

Authors:  Mohammed Eslam; Jacob George
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-10-22       Impact factor: 46.802

2.  Gamma-glutamyltransferase and risk of cardiovascular mortality: A dose-response meta-analysis of prospective cohort studies.

Authors:  Junna Wang; Dandan Zhang; Rongzhong Huang; Xingsheng Li; Wenxiang Huang
Journal:  PLoS One       Date:  2017-02-23       Impact factor: 3.240

3.  Implication of liver enzymes on incident cardiovascular diseases and mortality: A nationwide population-based cohort study.

Authors:  Kyung Mook Choi; Kyungdo Han; Sanghyun Park; Hye Soo Chung; Nam Hoon Kim; Hye Jin Yoo; Ji-A Seo; Sin Gon Kim; Nan Hee Kim; Sei Hyun Baik; Yong Gyu Park; Seon Mee Kim
Journal:  Sci Rep       Date:  2018-02-28       Impact factor: 4.379

4.  A Simplified Risk Scoring System to Predict Mortality in Cardiovascular Intensive Care Unit.

Authors:  Hendry Purnasidha Bagaswoto; Nahar Taufiq; Budi Yuli Setianto
Journal:  Cardiol Res       Date:  2019-07-31

5.  Cordycepin from Medicinal Fungi Cordyceps militaris Mitigates Inflammaging-Associated Testicular Damage via Regulating NF-κB/MAPKs Signaling in Naturally Aged Rats.

Authors:  Spandana Rajendra Kopalli; Kyu-Min Cha; Jae Youl Cho; Si-Kwan Kim; Sushruta Koppula
Journal:  Mycobiology       Date:  2022-02-17       Impact factor: 1.858

6.  Circulating liver enzymes and risks of chronic diseases and mortality in the prospective EPIC-Heidelberg case-cohort study.

Authors:  Verena Katzke; Theron Johnson; Disorn Sookthai; Anika Hüsing; Tilman Kühn; Rudolf Kaaks
Journal:  BMJ Open       Date:  2020-03-08       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.